off-patent drugs

off-patent drugs

see generic (2).
References in periodicals archive ?
The Off-patent Drugs Bill would create a duty for the UK Government to step in and seek to licence such re-purposed drugs.
The Off-Patent Drugs Bill would save millions of pounds and many lives by letting NHS doctors prescribe existing drugs for new uses.
The Off-patent Drugs Bill would improve access to low cost, effective treatments for a range of conditions - from breast cancer to multiple sclerosis - and I would urge our local MP to support it.
THE Off-Patent Drugs Bill will be voted on in Parliament on November 6.
The Global & USA Biosimilar Market Analysis to 2021 research report indicates a high market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry.
Nick Thomas-Symonds, who won Torfaen in last month's election, has won the backing of charity Breast Cancer Now for his Off-patent Drugs Bill.
In view of the lack of any firm dosage for neonates and infants, vancomycin has been included in the EMA list of off-patent drugs addressing unmet therapeutic needs in children.
The new price cuts are designed to save some 300 million euros ($390 million) on off-patent drugs but the EOF said its list contained "errors" and should not be relied on by other countries as a point of reference in setting their own prices.
In a paper recently published in Cell, they tested 2,600 off-patent drugs of which only about one per cent showed activity.
These drugs also offer some economic protection for larger companies, as they can allow weaker-selling or off-patent drugs to be paired with a stronger-selling or patented drug.
Experts expect that during the trade agreement talks, the United States will request that Korea enact a law similar to the United States Hatch-Waxman Act which provides incentives to support the development of generic versions of off-patent drugs and permit patent owners to recover time lost during FDA approval," Sunhee Lee, Of Counsel for Sughrue's Biotechnology/Pharmaceutical Group and a registered Korean patent attorney, said.
Manufacturer of generic drugs, Sandoz (owned by Novartis) is set buy Canada's Sabex for $565 million (CHF699 million) in a bid to boost its position in the North American market for off-patent drugs.